Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma

Melanoma Research

Volumn 15, Issue 3, 2005, Pages 205-207

  Schmittel, Alexander ^a   Scheulen, Max E ^b   Bechrakis, Nikolaos E ^a   Strumberg, Dirk ^b   Baumgart, Joachim ^c   Bornfeld, Norbert ^d   Foerster, Michael H ^a   Thiel, Eckhard ^a   Keilholz, Ulrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c MEDAC GMBH   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Cisplatin; Gemcitabine; Phase II; Treosulfan; Uveal melanoma

Indexed keywords

CISPLATIN; DEXAMETHASONE; GEMCITABINE; SEROTONIN 3 ANTAGONIST; TREOSULFAN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; UVEA MELANOMA;

ADULT; AGED; ANEMIA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKOPENIA; MALE; MELANOMA; MIDDLE AGED; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; UVEAL NEOPLASMS;

EID: 20544447078     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200506000-00010     Document Type: Article

References (15)

1. Fritz G, Hengstler JG, Kaina B. High-dose selection with mafosfamide results in sensitivity to DNA cross-linking agents: characterization of hypersensitive cell lines. Cancer Res 1997; 57:454-460.
2. Hartley JA, O'Hare CC, Baumgart J. DNA alkylation and interstrand crosslinking by treosulfan. Br J Cancer 1999; 79:264-266.
3. Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJE, Hungerford JL, et al. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 1999; 79:1487-1493.
4. Plunkett W, Gandhi V. Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif 2001; 19:21-45.
5. Keilholz U, Schuster R, Schmittel A, Bechrakis N, Siehl J, Foerster MH, et al. A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumors. Eur J Cancer 2004; 40:2047-2052.
6. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer 1995; 76:1665-1670.
7. Flaherty LE, Unger JM, Liu PY, Mertens WC, Sondak VK. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol 1998; 21:568-572.
8. Pyrhonen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992; 10:1919-1926.
9. Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002; 87:840-845.
10. Kivelä T, Suciu S, Hansson J, Kruit WH, Vuoristo MS, Kloke O, et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer 2003; 39:1115-1120.
11. Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 1988; 260:974-976.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216.
13. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10.
14. Leyvraz S, Bosshard W, Salmon R. Prolonged survival of patients with liver metastases from ocular melanoma: multicentric experience with fotemustine hepatic arterial infusion. J Clin Oncol 2002; 341:Abstract.
15. Egerer G, Lehnert T, Max R, Naeher H, Keilholz U, Ho AD. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients. Int J Clin Oncol 2001; 6:25-28.